GENSIGHT BIOLOGICS Revenue and Competitors
Estimated Revenue & Valuation
- GENSIGHT BIOLOGICS's estimated annual revenue is currently $14.4M per year.
- GENSIGHT BIOLOGICS's estimated revenue per employee is $155,000
Employee Data
- GENSIGHT BIOLOGICS has 93 Employees.
GENSIGHT BIOLOGICS's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Co-Founder, CEO | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | VP Regulatory Affairs Quality Assurance | Reveal Email/Phone |
6 | VP, Marketing | Reveal Email/Phone |
7 | Head Legal Affairs | Reveal Email/Phone |
8 | Clinical Operation Director | Reveal Email/Phone |
9 | Chief Technology Officer | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
GENSIGHT BIOLOGICS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is GENSIGHT BIOLOGICS?
N/A
Total Funding
93
Number of Employees
$14.4M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
GENSIGHT BIOLOGICS News
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing...
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal...
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal...
Paris - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the 'Company'), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today the success of ...
Paris - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the 'Company'), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has lau ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $23.3M | 93 | 45% | N/A |
#2 | $25.1M | 93 | -12% | N/A |
#3 | $21.1M | 93 | 24% | N/A |
#4 | $23.6M | 93 | 13% | N/A |
#5 | $13M | 93 | 0% | $47.6M |